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ABSTRACT 
 
Objectives: Osteoarthritis (OA) is a leading cause of disability, but the relationship 
with premature mortality remains uncertain. We aimed to investigate the relationship 
between OA and mortality from any cause and from cardiovascular disease (CVD).   
 
Methods: Electronic literature databases searches were conducted to identify 
prospective studies comparing mortality in a sample of people with and without OA. 
Risk of call-cause and CVD-mortality were summarized using adjusted hazard ratios 
(HRs) for joint-specific (hand, hip and knee) and joint non-specific OA. New data 
from the Progetto Veneto Anziani (PRO.V.A.) study were also included. 
 
Results: From the PRO.V.A. study (N=2,927), there was no significant increase in 
CVD mortality risk for participants with any-joint OA (N=1,858) compared to non-
OA (all-cause, HR=0.95; 95% CI: 0.77-1.15; CVD, HR=1.12; 95% CI: 0.82-1.54). 
On meta-analysis, seven studies (OA: 10,018/non-OA: 18,541), with a median 12-
year follow-up, reported no increased risk of any-cause mortality in those with OA 
(HR=1.10; 95% CI: 0.97-1.25). After removing data on hand OA, a significant 
association between OA and mortality was observed (HR=1.18; 95% CI: 1.08-1.28). 
There was a significant higher risk of overall mortality for (1) studies conducted in 
Europe, (2) patients with multi-joint OA; and (3) a radiological diagnosis of OA. OA 
was associated with significantly higher CVD mortality (HR=1.21; 95% CI: 1.10-
1.34). 
  
5 
 
Conclusions: People with OA are at increased risk of death due to CVD. The 
relationship with overall mortality is less clear and may be moderated by the presence 
of hand OA.  
 
Keywords: osteoarthritis; mortality; cardiovascular disease.  
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Osteoarthritis (OA) is a leading cause of years lived with disability worldwide.1,2 The 
leading symptom associated with OA is chronic musculoskeletal pain, which is 
associated with  mobility and function.3,4 Physical inactivity is independently 
associated with an increased risk of cardiovascular diseases (CVD) and mortality in 
the general population.5 Obesity is also commonly seen within the osteoarthritis 
population, whilst also being associated with morbidities such as type two diabetes, 
cancers and CVD. .6 
 
CVD are a leading cause of global mortality, with recent estimates demonstrating that 
CVD account for 17.3 million deaths globally.7 A recent meta-analysis demonstrated 
that people with OA are at increased risk of CVDs,8 which may also be influenced by 
an elevated chronic inflammatory status in some subgroups with OA.9 Death due to 
CVD is potentially preventable through appropriate timely pharmacological and 
non-pharmacological interventions10 Therefore, to identify people at higher risk 
of CVD mortality could be of considerable public health importance.   
Within the past decade, a number of observational studies have reported that people 
with OA are at increased risk of premature mortality compared to the general 
population.11–13 However, this evidence is heterogeneous and limited by the lack of 
adjustment for appropriate confounders.  
 
Given this, the purpose of this study was to: i) analyze data from a prospective cohort 
study on the risk of CVD mortality in OA compared to a non-osteoarthritis cohort, 
adjusting for important medical morbidities and other confounders; ii)  to 
systematically review the available literature and perform a meta-analysis to 
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determine whether people with OA present a differential risk of overall and CVD 
mortality than those without OA. We hypothesized that people with OA had a 
significant higher risk of overall and CVD death compared to those without OA.    
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MATERIALS AND METHODS 
 
Prospective cohort study 
 
Overall cohort 
Previously unpublished data from the Progetto Veneto Anziani (PRO.V.A. study) 
were used to investigate the risk of overall and CVD mortality in people with OA 
over a mean follow-up of 4.4 years. The Pro.V.A. study is an observational cohort 
study on the Italian population aged over 65 years. The study population initially 
included 3,099 older Caucasian adults (1,245 men/1,854 women), who were 
randomly selected between 1995 and 1997 using a multistage stratified method, in 
two North Italian towns (Camposampiero and Rovigo). Additional details about the 
study design has been previously reported.14  
 
Participant selection 
After excluding 172 participants without information about OA, data from 2,927 
participants (men:1,179/ women:1,748) were gathered. Hand, hip and knee OA 
presence was assessed through medical history and records, previous x-ray reports, 
and clinical evaluation. This latter evaluation included for the hand the presence of 
Heberden nodes, stiffness, pain at passive moment; for the knee: deformity, pain at 
passive movement, reduced passive mobility and crepitus; for the hip: pain at passive 
movement, rotation and palpation, and reduced external rotation. The diagnosis of OA 
was finally confirmed by a rheumatologist using a standardized algorithm.15 Mortality 
was ascertained through direct reviewing of single death certificate, and the main 
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cause of death was recorded using the ICD-9. Death for CVD reasons was defined 
using the ICD-9 codes from 390 to 459.   
 
Statistical analysis 
Due to the small number of death attributed to non-CVD, it was not possible to 
appropriate analyses overall mortality, over CVD mortality from this dataset. 
Accordingly, the risk of CVD mortality associated with OA was investigated using 
multivariate Cox’s regression analysis adjusted for known clinical factors associated 
with mortality. These included: age (continuous); gender; body mass index 
(continuous); educational level (< 5 vs. >5 years); alcohol drinking (yes vs. no); 
monthly income (>500 vs. <500 €); physical activity level (>4 vs. <4 h/week); 
presence at baseline of CVD, fractures, chronic obstructive pulmonary disease, 
orthostatic hypotension (difference in systolic of 20 mmHg or diastolic of 10 mmHg 
between orthostatism and clinostatism)16, hypertension (use of anti-hypertensive 
medications, mean of systolic blood pressure>140 or mean diastolic blood 
pressure>90 mmHg)17, diabetes (fasting plasma glucose>126 mg/dl, glycosilated 
hemoglobin>7% or use of anti-diabetic medications)18, frailty (according with a 
modified Fried’ index)19, cancer (all yes vs. no); number of medications (continuous); 
smoking status (current/former vs. never); activities of daily living assessed (ADLs)20, 
Mini-Mental State Examination (MMSE)21, Geriatric Depression Scale22, Geriatric 
Nutrition Risk Index scores(GNRI) 23 (all as continuous). For all the scores, with 
exception of GDS, the higher the score the better the status. In the multivariate 
analysis, data were missing for 258 (=8.8%) of the participants, mainly for 
information about orthostatic hypotension (n=142), glycosilated hemoglobin (n=244), 
and MMSE (n=125).  
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Risk estimates were computed for any joint and anatomical region affected (hand, hip 
or knee). All analyses were performed using the SPSS 21.0 for Windows (SPSS Inc., 
Chicago, IL). Statistical significance was assumed for a two-tailed p-value <0.05. 
 
Systematic Review 
 
This systematic review was conducted following the MOOSE (Meta-analysis of 
observational studies in epidemiology) guidelines and data reporting was performed 
in agreement with the PRISMA (Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses) guidelines.24,25 
 
Data sources and literature search strategy 
We created search strategies for the concepts of “osteoarthritis” and “mortality” using 
a combination of standardized terms and keywords harvested from indices, thesauri, 
and on-topic articles (Supplementary Table 1). The electronic databases (PubMed, 
Embase, Scopus, CiNAHL [via Ebsco], ASSIA [via Proquest], and Social Work 
Abstracts [via Ebsco]), were search from database inception to 17th November 2015. 
We further conducted a manual search of reference lists of included and other relevant 
articles. Authors were contacted in case of lacking information. All articles were 
reviewed for inclusion by two independent reviewers (NV and BS). Any 
discrepancies were resolved by consensus with a third reviewer (EM).  
 
Study selection  
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Prospective, observational cohort studies were eligible for inclusion if they: reported 
data on OA diagnosed with clinical and/or radiological assessment; reported mortality 
risk estimates (hazard ratios [HRs]) along with their 95% confidence intervals 
(95%CI); and included a control group without OA. Intervention studies and studies 
including only participants with joint replacement (e.g. total hip or total knee 
arthroplasty) were excluded.  
 
Data extraction  
Overall and CVD risk estimates (adjusted for the maximum number of confounders 
available) comparing people with OA against people without OA were gathered. One 
investigator (NV) extracted data from the included articles and two independent 
investigators (CL and EC) verified these data. For each paper we extracted also data 
about authors, publication year, study location, setting, participant characteristics by 
presence of OA (e.g. age, percentage of women, CVD, body mass index [BMI]), 
follow-up duration (in years), number and list of covariates used in statistical 
analyses). Study authors were contacted if necessary.  
 
Outcomes 
The primary outcome was: - overall mortality in OA compared to non-OA 
participants. Secondary outcomes included: overall mortality based on anatomical site 
of OA (i.e. hand, hip and knee) and CVD mortality.  
 
Assessment of study quality  
The Newcastle-Ottawa Scale (NOS)26 was used to evaluate study quality. The NOS 
assigns a maximum of nine points to studies of highest quality according to three 
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quality parameters: selection (four points), comparability (two points), and outcome 
(three points). Each included study was assessed by three reviewers. If discrepancies 
arose in appraisal, these were addressed by a joint re-evaluation of the article (MS, 
SM and TS).  
 
Data synthesis and statistical analysis  
To compensate for potential between-study heterogeneity, we calculated a pooled HR 
using DerSimonian-Laird random-effect model.27 Statistical heterogeneity across 
studies was assessed using the Cochrane I2 metric and chi-square statistics.28 Since the 
diagnostic criteria for OA involve clinical and radiological parameters29–31 and 
evidence has suggested that radiological findings may poorly correlate to clinical 
presentation32, in absence of universally agreed recommendations we initially 
(primary analyses) pooled HRs of overall mortality as provided by the studies 
regardless of method of diagnosis.. Joint specific estimates for overall mortality and 
CVD specific death were computed. Within-study pooled estimates were also 
calculated as necessary (e.g. only joint-specific HRs provided).  
 
Given significant statistical heterogeneity (I2>50%) 33, we conducted meta-regression 
analyses investigating the following moderators: continent (Europe vs. others), type 
of diagnosis of OA (clinical vs. radiological vs. combined); follow-up duration, NOS 
score, number of adjustments (all by median value); death ascertainment (using death 
certificates or other tools), and number of sites affected.  
 
Publication bias was assessed by visually inspecting funnel plots and using the Begg-
Mazumdar Kendall tau34 and the Egger bias test.35 To account for potential 
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publication bias, we used a ‘trim-and-fill’ method, based on the assumption that the 
effect sizes of all the studies are normally distributed around the center of a funnel 
plot. In the event of asymmetries, this procedure adjusts for the potential effect of 
unpublished (imputed) studies.36 All analyses were performed using Comprehensive 
Meta-Analysis 3. 
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RESULTS 
 
Prospective cohort study 
 
Baseline characteristics 
In the PRO.V.A. study, participants with OA (N=1,858; 63.5%) were significantly 
older, with a greater proportion of women compared to those without OA (n=1,069) 
(Table 1). Subjects with OA had also a significantly higher presence of potential risk 
factors for early mortality, including lower GNRI, preserved number of ADLs, and 
higher presence of depressive symptoms, frailty, osteoporotic fractures, orthostatic 
hypotension and hypertension, diabetes and CVD, compared to the non-OA group 
(Table 1).   
 
Follow-up and CVD mortality  
Over the 4.4 years of follow-up, 745 participants (men:380/women:365) died. Using 
Cox’s regression analysis and taking participants with no OA for reference, no 
significant increased risk of death in people with OA emerged (HR=0.95 [95% 
CI:0.77-1.15], p=0.58) (Table 2). On the multivariate analysis (Supplementary Table 
2), the significant predictors of death were diabetes (HR=1.50 [95% CI: 1.20-1.88], 
p<0.001), CVD (HR=1.50 [95% CI: 1.23-1.82], p<0.001), COPD (HR=1.34 [95% CI: 
1.04-1.72], p=0.03), cancer (HR=1.37 [95% CI: 1.03-1.81], p=0.03) and frailty 
(HR=2.12 [95% CI: 1.52-2.97], p<0.001). Higher MMSE and GNRI were protective 
for mortality (HR=0.96 [95% CI: 0.94-0.98], p<0.001 and HR=0.96 [95% CI: 0.95-
0.97], p<0.001, respectively). A similar lack of association was also found when 
individually analyzing OA by anatomical site (hand, hip or knee) or when lower limbs 
OA was analyzed (HR=0.97 [95% CI: 0.82-1.14], p=0.48). Finally, OA did not 
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significantly increase the risk of CVD death (total number of events, n=373; HR= 
1.12 [95% CI: 0.83-1.55], p=0.53). Other causes of death could not be investigated 
(respiratory, n=128; cancer, n=58; others=186). 
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Systematic Review 
 
Search results 
In total, 2,139 non-duplicated articles were identified. After excluding 2,124 articles 
based on title/abstract review, 15 articles were fully retrieved and six were included37–
42 along with data from the PRO.V.A study (Supplementary Figure 1). For one 
conference abstract38, additional data were gathered from the Authors.  
 
Study and Population Characteristics 
As reported in Table 3, the seven meta-analyzed studies followed 28,559 participants 
(OA: 10,018/non-OA: 18,541) for a median duration of 12 (IQR: 6.5 to 18) years. 
Participants were all community-dwellers, mainly European (N=4; 57%). The 
assessment of OA was heterogeneous across studies with two 37,38 and five 
(PRO.V.A) and 39–42 reporting a radiological and a combined (clinical + radiological) 
assessment, respectively. Different methods of death ascertainment were also 
observed, but six out of seven were of high reliability and quality 37–41. Finally, among 
the studies included, four provided data also for CVD mortality (PRO.V.A) and 
37,38,41.  
 
Quality Assessment 
The median NOS score was seven (IQR: 6-8). The most common source of bias was 
the ascertainment of exposure (particularly missing data on radiological or 
standardized criteria for the assessment of OA; Supplementary Table 3). On the 
other, only one study has not considered pertinent linkage to high-quality records.42  
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Hazard ratios for overall mortality 
For the calculation of pooled overall mortality estimate we used joint-specific HRs for 
three studies.40–42  Compared to those without OA, participants with OA had no 
significantly different risk for overall mortality (HR=1.10; 95% CI: 0.97 to 1.25; 
p=0.12; I2=67%; Figure 1), also after adjusting for a median of 13 (IQR: 9 to 14) 
confounders (Supplementary Table 4). After excluding studies providing risks for 
site specific OA, the pooled risk of death from all causes was found to be significant 
with low heterogeneity (HR=1.18; 95% CI: 1.08 to 1.28; p<0.001; I2=47%). 
 
Sub-group analyses demonstrated that the presence of OA in hand, hip and knee was 
not associated with an increased risk of mortality (Figure 1). Funnel plot inspection 
indicated that publication bias was unlikely, as confirmed by Begg’s (p=0.90) and 
Egger’s tests (p=0.89). 
 
Hazard ratios for cause-specific (CVD) mortality 
In four studies (PRO.V.A) and 37,38,41, OA was significantly associated with CVD 
death without heterogeneity or publication bias (HR=1.21; 95% CI: 1.10 to 1.34; 
p<0.001; I2=0%). Cause-specific mortality for single joints could not be computed 
due to the limited number of studies. 
 
Meta-regression analysis 
Since the overall mortality analyses showed evidence of heterogeneity (I2=67%), a 
meta-regression analysis was undertaken (Table 4). In a great part of the strata 
heterogeneity remained high. However, in some studies there was a significantly 
higher risk of overall mortality and a moderate-to-substantial reduction of between-
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study heterogeneity: European studies; death ascertainment using death certificates; 
multiple joints affected; radiological diagnosis of OA.  
 
Since the pooled HR for hand OA on overall mortality appeared to be marginally 
protective (p=0.07),  a sensitivity analysis was conducted to remove the effect of 
three datasets (PRO.V.A 40,41). This analysis demonstrated that for hand OA, 
pooled HR for mortality was 1.18 (95% CI: 1.07 to 1.30; p=0.001; I2=48%) 
[(PRO.V.A) and 33-35,37,38]
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DISCUSSION 
 
To the best of our knowledge, this is the first meta-analysis investigating the 
association between OA and mortality. The seven meta-analyzed studies (including 
10,018 participants with and 18,541 people without OA) demonstrated that the 
presence of OA was not associated with mortality, although this appeared to 
substantially depend on between-study heterogeneity. When analyzing studies 
conducted in Europe, we observed a significantly higher risk of mortality and lower 
heterogeneity. A significant confounding factor to mortality seems to be the inclusion 
of the studies reporting data on hand OA. Finally, when considering cause-specific 
mortality, it appears that people with OA are at increased risk of CVD mortality.  
 
It is known that participants with OA frequently exhibit a number of medical 
morbidities which increase their risk for death.8,39,43 In the PRO.V.A. study, people 
with OA reported a higher presence of frailty, cardiovascular and metabolic diseases 
than those without. The role of these potential confounders in explaining the 
relationship between OA and mortality seems to be relevant44, consistent with the 
findings of a recent large scale prospective study37 reinforcing the importance of CVD 
risk in influencing mortality of people with OA. In the PRO.V.A. study we have tried 
to better identify the specific risk factors for mortality in participants with OA, in 
order to propose appropriate and specific interventions. Independent predictors of 
early death significantly different between those with OA and those without were 
diabetes, CVD, frailty and poorer nutrition index. Hierarchically, frailty seems to be 
the most important and, since frailty is reversible if appropriately treated45, our 
findings suggest that people with OA should be more active to reduce the risk of 
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premature death. Thus, the association between OA and overall mortality appears to 
be more related to confounders than for OA itself. This is likely supported in our 
meta-analysis by strata analysis as the number of adjustments appeared to partially 
explain between-study heterogeneity. Strata analyses suggested not only that ethnicity 
could be a potential risk modifier, but also that evidence of an association may depend 
on study methodology. Particularly, our study highlights the need of providing 
evidence-based or at least consensus-based criteria for homogenous case 
ascertainment. 
 
The secondary analyses explored whether the anatomical site of OA was associated 
with earlier mortality. Hip or knee OA did not predict early death, while for hand OA 
there was a trend towards a significant reduction in mortality. Since lower limbs OA 
are associated with high rate of disability and other risk factors for mortality46, more 
research is needed to better understand the role of lower limbs OA in predicting 
mortality. Regarding hand OA, one study40 suggests that not only radiographic, but 
also symptomatic hand OA is protective for mortality, although both these conditions 
are associated with a higher incidence of CVD.40 A possible reason is that hand OA 
was associated with a reduced cancer-related mortality.40 The reasons of this 
association are not known and further research is obviously needed.   
 
Our data from the meta-analysis suggests that people with OA are at increased risk of 
premature mortality due to CVD also after accounting for potential confounders. 
People with OA are known to have high levels of CVD8,47, an increased inflammatory 
profile9 and low levels of physical activity48, all of which may predispose people with 
OA to premature mortality due to CVD. Moreover, they use a higher proportion of 
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analgesic medications with an unfavorable CVD profile.49 Given that exercise has 
been reported as being equally effective in managing some types of CVD as 
pharmacological interventions50, interventions targeting physical activity, frailty and 
inappropriate medication should be a priority among people with  OA at higher risk of 
mortality. An indirect confirmation of this hypothesis was given by a recent study 
showing that patients with knee OA who underwent joint replacement had a lower 
risk of future CVD events, potentially due to an increased post-operative physical 
activity levels and decreased use of analgesics compared to pre-operatively. 51   
 
Whilst our primary data and meta-analyses are novel, the findings of our work should 
be interpreted within its limitations. First, there was some evidence of statistical 
heterogeneity. However, we attempted to address the issue of between study 
heterogeneity, as advised by the MOOSE guidelines24, suggesting some factors could 
moderate the association between OA and mortality. Second, it was not possible to 
stratify our meta-analysis results according to gender, although is known that women 
are at higher risk of OA and its complications.52 Third, no study included considered 
nor the duration of OA at inclusion, nor its progression (clinically or radiologically) 
neither the incidence of new cases within the follow-up period. It is therefore unclear 
whether OA disease progression influenced the outcomes. Furthermore, there was no 
record as what treatments were prescribed and adhered to in the OA cohort, which 
clearly might influence mortality. Therefore it is unclear whether disease medication 
(or symptom modification) impacted on mortality. Fourth, there was some 
discrepancy in the prevalence of OA across the PRO.V.A. study and the meta-
analysis. Reasons for this difference may include: ii) the higher mean age of the 
PRO.V.A. cohort; and ii) the potential higher prevalence of OA in Italy than other 
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countries.6 Fifth, we did not assess the association of OA with specific cause mortality 
other than CVD mortality. This was because there remains limited evidence on other 
cause mortality for people with OA. Consequently such analyses would have been 
underpowered and potentially meaningless. However, this should be considered in the 
future once more studies are published in this area. Finally, the analyses 
pertaining to site-specific OA are preliminary and should be interpreted with 
cautious. These are based on a limited number of studies for each outcome, and 
appeared to be contrasting (lower limbs OA seems to increase and hand OA 
seems to decrease the risk of death). Further analyses should be undertaken to 
re-explore the potential importance of joint location with mortality as more 
studies are published in this area 
 
The strengths of this paper are that it  is the first meta-analysis to: i) assess for the 
association between OA and mortality; and ii) has specifically  explored for factors to 
explain for the heterogeneity in individual study results. This therefore provides 
important knowledge to increase the awareness of CVD in this population. This is 
important since CVD is potentially preventable through appropriate timely 
interventions.10 to impact on the health of people with osteoarthritis.  Secondly, 
since the cohorts included in these analyses were large, the collective pooled analyses 
provided lower risk of committing a type two statistical error which would have 
occurred if these studies were interpreted individually.  Finally, in the adjusted 
analyses, a number and wide variety of different confounders were included in the 
analysis to be able to answer our research question with these potentially factors 
accounted for.  
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In conclusion, it appears that people with OA are at increased risk of CVD-specific 
mortality while the association with overall mortality is less clear. Additional 
prospective research is required to further explore the relationship between OA and 
mortality.  
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Figure 1. Meta-analysis and pooled hazard ratios of mortality in participants with osteoarthritis from prospective cohort studies (*, for this study 
the estimate was obtained by pooling within-study risks for symptomatic and radiographic osteoarthritis; **, for this study the estimate was 
obtained by meta-analysing within-study risks for different joints after pooling hazard ratios for only symptomatic, only radiographic and painful 
radiographic osteoarthritis). 
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Hazard ratio and 95% CI 
Hazard  Lower  Upper  
ratio limit limit Z-Value p-Value 
Barbour. 2015 (hip) 1.14 1.05 1.24 3.088 0.002 
Castano Betancourt. 2013 (hip and/or knee) 1.23 1.11 1.37 3.856 0.000 
Cacciatore. 2014 (any joint) 1.28 0.98 1.67 1.815 0.069 
Haugen. 2013 (hand) * 0.81 0.66 0.99 -2.037 0.042 
Kluzek. 2015 (hand + knee [pooled]) ** 0.67 2.67 0.830 0.407 
Liu. 2015 (knee) * 1.47 0.94 2.31 1.680 0.093 
PRO.V.A. study (hand and/or hip and/or knee) 0.95 0.78 1.16 -0.501 0.616 
1.10 0.97 1.25 1.540 0.124 
Haugen. 2013 * 0.81 0.66 0.99 -2.037 0.042 
Kluzek. 2015 ** 0.97 0.76 1.26 -0.236 0.813 
PRO.V.A. study 1.00 0.78 1.29  0.000 1.000 
0.91 0.79 1.04 -1.447 0.148 
Barbour. 2015 1.14 1.05 1.24 3.088 0.002 
PRO.V.A. study 0.96 0.77 1.20 -0.361 0.718 
1.08 0.92 1.26 0.639 0.333 
Kluzek. 2015 ** 1.47 1.08 2.01 2.431 0.015 
Liu. 2015 * 1.47 0.94 2.31 1.680 0.093 
PRO.V.A. study 0.86 0.66 1.12 -1.118 0.264 
1.21 0.82 1.78 1.939 0.348 
Kluzek. 2015 (hand + knee [pooled]) ** 1.50 0.82 2.74 1.317 0.188 
Barbour. 2015 1.24 1.09 1.41 3.276 0.001 
Castano Betancourt. 2013 (hip and/or knee) 1.16 0.95 1.42 1.447 0.148 
PRO.V.A. study 1.12 0.83 1.55 0.711 0.477 
1.21 1.10 1.34 3.747 <0.001 
Overall (I
2
=67% [p=0.006]) 
Overall (I
2
=2% [p=0.36]) 
Overall (I
2
=51% [p=0.15]) 
Overall (I
2
=76% [p=0.017]) 
Overall (I
2
=0% [p=0.79]) 
ALL-CAUSE MORTALITY (any joint OA) 
ALL-CAUSE MORTALITY (hand OA) 
ALL-CAUSE MORTALITY (hip OA) 
ALL-CAUSE MORTALITY (knee OA) 
CV MORTALITY (any joint OA) 
1.34 
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Table 1. Baseline characteristics by diagnosis of osteoarthritis at baseline: the 
PRO.V.A. study.   
 
*Unless otherwise specified, p values are adjusted for age and gender using a general 
linear model or logistic regression, as appropriate.  
†Not adjusted for age.  
‡Not adjusted for gender.  
 
Abbreviations: ADL: activities of daily living; BMI: body mass index; COPD: 
chronic obstructive pulmonary disease; CVD: cardiovascular diseases; GDS: Geriatric 
Patients’ characteristics  OA 
(n=1,858) 
No OA 
(n=1,069) 
p value* 
Age (years), Mean±SD 77.5±7.9 74.6±7.6 <0.001† 
Female gender, % 66.4 48.2 <0.001‡ 
General and anthropometric 
characteristics  
   
Alcohol drinking, % 65.1 72.8 <0.001 
Current/former smokers, % 33.3 47.3 0.60 
Educational level > 5 years, % 13.0 17.4 0.002 
Physical activity≥4 h/week, %  19.0 22.8 <0.001 
Monthly income (>500 €), % 36.1 44.7 <0.001 
GNRI (score),  Mean±SD 105.6±5.7 106.5±5.6 0.048 
ADL (score),  Mean±SD 4.6±1.8 5.4±1.4 <0.001 
BMI (kg/m2),  Mean±SD 28.0±4.8 26.8±4.2 <0.001 
GDS (score),  Mean±SD 9.5±6.0 8.1±5.0 <0.001 
MMSE (score),  Mean±SD 22.3±7.0 23.8±6.2 0.51 
Medical conditions    
Frailty, % 12.6 4.9 <0.001 
Fractures, % 11.6 5.9 <0.001 
Diabetes, % 17.7 14.7 0.03 
Hypertension, % 76.3 70.8 0.001 
Orthostatic hypotension, % 34.1 28.8 0.004 
CVD, % 25.5 20.4 0.002 
COPD, % 10.0 9.1 0.44 
Cancer, % 7.9 7.4 0.67 
Number of drugs, Mean±SD 3.1±2.2 2.4±2.1 <0.001 
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Depression Scale; GNRI: Geriatric Nutrition Risk Index; MMSE: Mini Mental State 
Examination; OA: osteoarthritis; SD, standard deviation.  
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Table 2: Association of osteoarthritis (OA) with the onset of all-cause mortality in the 
PRO.V.A. study cohort. 
 
 
Data are presented as hazard ratios and 95% confidence intervals [HR (95%CI)]. 
 
*The fully-adjusted model  includes: age (continuous); gender; body mass index 
(continuous); educational level (< 5 vs. >5 years); alcohol drinking (yes vs. no); 
monthly income (>500 vs. <500 €); physical activity level (>4 vs. <4 h/week); 
presence at baseline of cardiovascular diseases, fractures, chronic obstructive 
pulmonary disease, orthostatic hypotension, hypertension, diabetes, frailty, cancer (all 
yes vs. no); number of medications (continuous); smoking status (current/former vs. 
never); Activities of Daily Living, Mini-Mental State, Geriatric Depression Scale, 
Geriatric Nutrition Risk Index scores (all as continuous).  
 
 Events 
(N) 
Participants 
(N) 
Unadjusted 
HR (95%CI) 
p– 
value 
Fully-
adjusted * 
HR (95%CI) 
p–
value 
No OA 241 1,068 reference reference 
Presence of 
OA 
504 1,857 
1.16 (0.96-
1.40) 
0.12 
0.95 (0.77-
1.15) 
0.58 
Hand OA 180 695 
1.13 (0.89-
1.43) 
0.33 
1.00 (0.78-
1.29) 
0.99 
Hip OA 231 966 
1.07 (0.87-
1.33) 
0.52 
0.96 (0.77-
1.20) 
0.69 
Knee OA 140 549 
1.05 (0.81-
1.35) 
0.74 
0.86 (0.66-
1.12) 
0.25 
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Table 3. Characteristics of the studies according to the presence of osteoarthritis or not.   
First 
author, 
year 
 
Continent 
(Country) 
Setting 
Diagnosis  
criteria for  
OA 
OA N 
Mean age 
(SD) 
Females 
(N) 
CVD  
(N) 
Mean BMI 
(SD) 
Death 
ascertainment 
Follow-
up 
(years) 
Adjustments 
(N) 
NOS 
score 
Barbour, 
2015 
North America 
(USA) 
Community Radiological 
Yes 635 72.7 (5.3) 635 53 26.7 (4.6) Phone calls + 
death certificates 
16 7 8 
No 7254 71.2 (5.0) 7254 464 26.5 (4.6) 
Castano 
Betancourt, 
2013 
Europe (The 
Netherlands) 
Community Radiological 
Yes 4733 > 55 2721 -- -- 
GP records 5 11 7 
No 6261 > 55 -- -- -- 
Cacciatore, 
2014 
Europe (Italy) Community 
Clinical + 
Radiological 
Yes 698 74.8 (6.5) 559 -- 27.0 (5.1) 
Death certificates 12 13 6 
No 590 72.7 (6.9) 175 -- 25.8 (4.5) 
Haugen, 
2015 
North America 
(USA) 
Community 
Clinical + 
Radiological 
Yes 1162 66.3 (7.6) 422 55 27.9 (4.6) Linkage to 
different 
registries 
20 14 9 
No 622 57.6 (6.4) 303 37 27.4 (4.5) 
Kluzek, Europe (UK) Community Clinical + Yes 689 57.5 (6.0) 709 31 -- Death certificates 23 13 9 
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2015 Radiological No 940 55.0 (5.7) 940 35 -- 
Liu, 2015 Asia (China) Community 
Clinical + 
Radiological 
Yes 244 
62.0  
(10.2) 
163 -- 23.7 (3.7) Interview with 
relatives 
8 7 8 
No 1806 56.0 (7.7) 877 -- -- 
PRO.V.A. 
study 
Europe (Italy) Community 
Clinical + 
Radiological 
Yes 1857 77.5 (7.9) 1233 473 28.0 (4.8) 
Death certificates 4 21 7 
No 1068 74.6 (7.6) 515 218 26.8 (4.2) 
 
Abbreviations: BMI: body mass index; CVD: cardiovascular disease; GP: general practitioner; NOS score: Newcastle Ottawa scale score; OA: 
osteoarthritis; SD: standard deviation.  
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Table 4. Adjusted all-cause mortality risk for strata of different moderators  
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Moderator Strata Analysis details Adjusted HRs 
Continent 
 
 
Europe 
 
 
 
 
Other 
 
 
 
 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
P-value * 
1.18 (1.08-1.28) 
<0.001 
47% (0.13) 
4 
 
1.06 (0.80-1.25) 
0.68 
82% (0.004) 
3 
 
0.82 
Study quality† 
 
 
NOS score 
≤7 
 
 
 
 
NOS score 
>7 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
P-value* 
1.14 (0.96-1.36) 
0.13 
64% (0.06) 
3 
 
1.09 (0.84-1.39) 
0.53 
74% (0.01) 
4 
 
0.74 
Number of 
adjustments † 
 
 
<13 
 
 
 
 
≥13 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
P-value * 
1.18 (1.10-1.27) 
<0.0001 
8% (0.34) 
3 
 
1.00 (0.81-1.26) 
0.95 
63% (0.05) 
4 
0.18 
Follow-up 
duration † 
 
 
<15 
 
 
 
 
≥15 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
P-value* 
1.17 (1.00-1.38) 
0.05 
53% (0.09) 
4 
 
1.02 (0.76-1.36) 
0.91 
79% (0.008) 
3 
 
0.39 
Diagnosis of 
death 
 
 
Death 
certificates 
 
 
 
 
Others 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
 
P-value * 
1.18 (1.08-1.28) 
<0.001 
47% (0.13) 
4 
 
1.06 (0.80-1.25) 
0.68 
82% (0.004) 
3 
 
0.82 
Diagnosis of 
osteoarthritis 
 
 
Radiological 
+ clinical 
 
 
Pooled estimate, HR (95%CI) 
P-value for HR 
Heterogeneity, I2 (P-value) 
Number of studies 
1.07 (0.85-1.34) 
0.57 
65% (0.02) 
5 
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Bolded HR values: p<0.05 
Abbreviations: HR: hazard ratio; NOS: Newcastle-Ottawa Scale 
* The P-value for the t-test between the two statistical analysis strata according to 
meta-regression procedure. 
† Stratification was performed by median NOS score, median follow-up time and 
median number of adjustments as appropriate.  
 
